KR890010200A - 왁찐류 - Google Patents

왁찐류 Download PDF

Info

Publication number
KR890010200A
KR890010200A KR1019880017199A KR880017199A KR890010200A KR 890010200 A KR890010200 A KR 890010200A KR 1019880017199 A KR1019880017199 A KR 1019880017199A KR 880017199 A KR880017199 A KR 880017199A KR 890010200 A KR890010200 A KR 890010200A
Authority
KR
South Korea
Prior art keywords
aro
toxic
microorganism
microorganism according
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019880017199A
Other languages
English (en)
Other versions
KR970010759B1 (ko
Inventor
도우건 고든
네빌 챠트필트 스티븐
Original Assignee
원본미기재
더 웰컴˙화운데이숀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 웰컴˙화운데이숀 리미티드 filed Critical 원본미기재
Publication of KR890010200A publication Critical patent/KR890010200A/ko
Application granted granted Critical
Publication of KR970010759B1 publication Critical patent/KR970010759B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

왁찐류
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 감염후 일수에 따라 지라내의 생존력 있는 유기체의 수의 변화를 나타낸 그래프이다.

Claims (17)

  1. 방향족 생합성 경로에서 두개의 분리된 유전자에 비-환원성 돌연변이를 내포하고 있는 독성 약화 미생물.
  2. 제1항에 있어서, 미생물 박테리아 병원체임을 특징으로하는 독성 약화 미생물.
  3. 제2항에 있어서, 박테리아 병원체가 침입성 유기체 임을 특징으로하는 독성 약화 미생물.
  4. 제1항 내지 제3항중 어느 한항에 있어서, 비-환원성 돌연변이가 aro A 유전자에서 발생함을 특징으로하는 독성 약화 미생물.
  5. 제1항 내지 제4항중 어느 한항에 있어서, 이차 비-환원성 돌연변이가 aro C, aro D 또는 aro E 유전자 중 하나에서 발생함을 특징으로하는 독성 약화 미생물.
  6. 제1항 내지 제5항중 어느 한항에 있어서, 미생물이 살모넬라, 보르데텔라, 헤모필러스, 랩토스피라, 스트랩토코커스, 나이제리아 및 미코박테리아 속에서 선택됨을 특징으로하는 독성 약화 미생물.
  7. 제1항 내지 제6항중 어느 한항에 있어서, 미생물이 S. 타이피, S. 타이피무리엄, S. 더블린 또는 S. 콜레라수스 미생물로 부터 선택됨을 특징으로하는 독성 약화 미생물.
  8. aro A aro C, Aro A aro E 또는 aro A aro D 비-환원성 돌연변이 중 하나를 내포하고 있는 S. 타이피 균주 Ty 2.
  9. 수탁 번호 제12164호, 제12165호, 제12209호로 기탁된 S. 타이피의 독성 약화 균주.
  10. 제1항 내지 제10항중 어느 한항에 있어서, 이형의 항원을 형질 발현할 수 있는 독성 약화 미생물.
  11. 제1항 내지 제10항중 어느 한항에 있어서, 이형의 항원에 대한 구조 유전자를 코오딩한 DNA 서열을 갖는 형질 발현 카세트를 포함하는 독성 약화 미생물.
  12. 제1항 내지 제10항중 어느 한항에 있어서, 포유동물의 치료 또는 예방적 치료에 사용하는 독성 약화 미생물.
  13. 제8항 또는 제9항에 있어서, 인체 장티푸스의 예방적 치료에 사용되는 독성 약화 미생물.
  14. 약제학적으로 인정되는 부형제와의 혼합물 형태로 제1항 내지 제10항중 어느 한항에서 규정된 독성 약화 박테리아를 포함하는 약제학적 조성물.
  15. 일차 aro 유전자에 일차 비-환원성 돌연변이를 함유하는 미생물에 있어서 이차 aro 유전자로 이차 비-환원성 유전자로 도입하는 것을 포함하는 독성 약화 미생물을 생성하는 방법.
  16. 제13항에 있어서, 이차 돌연변이가 트랜스포존 돌연변이 유발에 의해 도입되는 것을 특징으로하는 방법.
  17. 제13항에 있어서, 이차 aro 유전자의 비-환원성 돌연변이체를 결합시킨 벡터로 미생물을 형질 변환 시킴으로서 이차 돌연변이를 도입하고 상기 이차 유전자의 돌연변이체를 유기체 자신의 염색체로 재조합된 유기체를 선택하기 위해 스크리닝 하는 것을 특징으로하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880017199A 1987-12-23 1988-12-22 약독화된 살모넬라 박테리아, 이를 함유하는 약학 조성물 및 이 박테리아의 제조 방법 Expired - Lifetime KR970010759B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878730037A GB8730037D0 (en) 1987-12-23 1987-12-23 Vaccines
GB8730037 1987-12-23

Publications (2)

Publication Number Publication Date
KR890010200A true KR890010200A (ko) 1989-08-07
KR970010759B1 KR970010759B1 (ko) 1997-06-30

Family

ID=10628973

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880017199A Expired - Lifetime KR970010759B1 (ko) 1987-12-23 1988-12-22 약독화된 살모넬라 박테리아, 이를 함유하는 약학 조성물 및 이 박테리아의 제조 방법

Country Status (20)

Country Link
EP (1) EP0322237B1 (ko)
JP (1) JP2602970B2 (ko)
KR (1) KR970010759B1 (ko)
AT (1) ATE103331T1 (ko)
AU (1) AU619519B2 (ko)
BR (1) BR8807376A (ko)
CA (1) CA1327331C (ko)
DE (1) DE3888652T2 (ko)
DK (1) DK174952B1 (ko)
ES (1) ES2061700T3 (ko)
GB (1) GB8730037D0 (ko)
HU (2) HUT55242A (ko)
IE (1) IE65176B1 (ko)
IL (1) IL88766A (ko)
MY (1) MY104367A (ko)
NZ (1) NZ227472A (ko)
PH (1) PH31428A (ko)
RU (1) RU2114172C1 (ko)
WO (1) WO1989005856A1 (ko)
ZA (1) ZA889605B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626139B2 (en) * 1989-01-12 1992-07-23 Commonwealth Scientific And Industrial Research Organisation Avirulent salmonella vaccine
IE61635B1 (en) * 1990-03-13 1994-11-16 Trinity College Dublin Improvements in vaccines
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
DK0574466T3 (da) * 1991-03-05 1999-11-08 Wellcome Found Udtrykkelse af rekombinante proteiner i svækkede bakterier
TW201794B (ko) * 1991-05-03 1993-03-11 American Cyanamid Co
EP0692031B1 (en) * 1993-02-22 2007-04-11 The General Hospital Corporation Heterologous antigens in live cell vaccine strains
WO1998023763A1 (en) * 1996-11-29 1998-06-04 The General Hospital Corporation Heterologous antigens in live cell v. cholerae strains
GB9711964D0 (en) * 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
WO1999013053A1 (en) 1997-09-10 1999-03-18 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP0913480A3 (en) * 1997-11-03 2001-07-11 Smithkline Beecham Corporation Chorismate synthase
US6905691B1 (en) 1997-12-11 2005-06-14 Celltech Pharma Europe Limited Vaccines containing attenuated bacteria
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
RU2255763C2 (ru) * 2003-06-04 2005-07-10 ФГУП Государственный Научный Центр прикладной микробиологии Вакцина против сальмонеллеза свиней
JP4623625B2 (ja) 2003-07-24 2011-02-02 株式会社AMBiS ヘテロ型５量体組換えワクチン
FR2898276B1 (fr) * 2006-03-08 2008-07-25 Univ Claude Bernard Lyon Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus
JP6145046B2 (ja) * 2010-12-22 2017-06-07 インターベット インターナショナル ベー． フェー． 全身投与用の生細菌単離株を含むワクチン
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337314A (en) * 1979-05-23 1982-06-29 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines

Also Published As

Publication number Publication date
DK174952B1 (da) 2004-03-22
IE883839L (en) 1989-06-23
DE3888652T2 (de) 1994-07-07
HU890702D0 (en) 1991-01-28
NZ227472A (en) 1992-07-28
ATE103331T1 (de) 1994-04-15
WO1989005856A1 (en) 1989-06-29
DK412689D0 (da) 1989-08-22
HK1000469A1 (en) 1998-03-27
JP2602970B2 (ja) 1997-04-23
ES2061700T3 (es) 1994-12-16
HU216449B (hu) 1999-06-28
MY104367A (en) 1994-03-31
IE65176B1 (en) 1995-10-04
HUT55242A (en) 1991-05-28
IL88766A (en) 1995-07-31
EP0322237A1 (en) 1989-06-28
DK412689A (da) 1989-08-22
AU619519B2 (en) 1992-01-30
EP0322237B1 (en) 1994-03-23
KR970010759B1 (ko) 1997-06-30
RU2114172C1 (ru) 1998-06-27
GB8730037D0 (en) 1988-02-03
DE3888652D1 (de) 1994-04-28
AU2919389A (en) 1989-07-19
JPH02502785A (ja) 1990-09-06
BR8807376A (pt) 1990-03-20
PH31428A (en) 1998-11-03
CA1327331C (en) 1994-03-01
ZA889605B (en) 1990-08-29

Similar Documents

Publication Publication Date Title
KR890010200A (ko) 왁찐류
Hillman et al. Construction and characterization of an effector strain of Streptococcus mutans for replacement therapy of dental caries
DE69229221T2 (de) Expression rekombinanter proteine in attenuierten bakterien
Guerry et al. Molecular nature of two nonconjugative plasmids carrying drug resistance genes
Wilson et al. Interaction of Clostridium difficile and Escherichia coli with microfloras in continuous-flow cultures and gnotobiotic mice
Wilks et al. Periplasmic superoxide dismutase in meningococcal pathogenicity
Van Den Broek et al. The role of phenotypic variation in rhizosphere Pseudomonas bacteria
Iñón de Iannino et al. Molecular cloning and characterization of cgs, the Brucella abortus cyclic β (1-2) glucan synthetase gene: genetic complementation of Rhizobium meliloti ndvB and Agrobacterium tumefaciens chvB mutants
Yamamoto et al. Disruption of the genes for ClpXP protease in Salmonella enterica serovar Typhimurium results in persistent infection in mice, and development of persistence requires endogenous gamma interferon and tumor necrosis factor alpha
Schiemann et al. Anaerobic growth of Salmonella typhimurium results in increased uptake by Henle 407 epithelial and mouse peritoneal cells in vitro and repression of a major outer membrane protein
Mitra et al. Cell vacuolation, a manifestation of the El Tor hemolysin of Vibrio cholerae
Robbe-Saule et al. Characterization of the RpoS status of clinical isolates of Salmonella enterica
Merrell et al. Vibrio cholerae requires rpoS for efficient intestinal colonization
US11484585B2 (en) Live attenuated cholera vaccine with probiotic properties
Simms et al. Multiple genes repress motility in uropathogenic Escherichia coli constitutively expressing type 1 fimbriae
Karasawa et al. Distribution of the zot (zonula occludens toxin) gene among strains of Vibrio cholerae 01 and non-01
JPS58501325A (ja) 腸疾患用免疫賦与性経口ワクチン
Pelludat et al. Transfer of the core region genes of the Yersinia enterocolitica WA-C serotype O: 8 high-pathogenicity island to Y. enterocolitica MRS40, a strain with low levels of pathogenicity, confers a yersiniabactin biosynthesis phenotype and enhanced mouse virulence
Anthony et al. Isolation of a Francisella tularensis mutant that is sensitive to serum and oxidative killing and is avirulent in mice: correlation with the loss of MinD homologue expression
Pozzi et al. Host-vector system for integration of recombinant DNA into chromosomes of transformable and nontransformable streptococci
Takai et al. Effect of growth temperature on maintenance of virulent Rhodococcus equi
Sousa Pathogenicity mechanisms of prokaryotic cells: an evolutionary view
Snellings et al. Characterization of Shigella type 1 fimbriae: expression, FimA sequence, and phase variation
Weir et al. Identification of type 4 pili in Kingella denitrificans
Baron et al. Transfer of plasmid-borne beta-lactamase in Neisseria gonorrhoeae

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19881222

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19931216

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19881222

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19961228

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19970603

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19970922

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19971107

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19971107

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 20000624

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20011101

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20021025

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20031023

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20041025

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20051025

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20061026

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20071026

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20081024

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20091022

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20101027

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20111019

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20111019

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term